- Conditions
- Spinal Muscular Atrophy Type 3, Mitochondrial Myopathy
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 8 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Spinal Muscular Dystrophy, Neuromuscular Disability
- Interventions
- Assisted Standing Treatment Program
- Other
- Lead sponsor
- Gillette Children's Specialty Healthcare
- Other
- Eligibility
- 3 Years to 14 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy (DMD)
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Boston, Massachusetts • New York, New York
- Conditions
- Type 2 Spinal Muscular Atrophy
- Interventions
- OAV101, Sham control
- Genetic · Procedure
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Farmington, Connecticut • Chicago, Illinois • Strasburg, Pennsylvania + 2 more
- Conditions
- Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy
- Interventions
- Observational
- Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Spinal Muscular Atrophy
- Interventions
- NMD670, Placebo
- Drug
- Lead sponsor
- NMD Pharma A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Palo Alto, California • Kansas City, Kansas + 6 more
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Onasemnogene Abeparvovec-xioi
- Biological
- Lead sponsor
- Novartis Gene Therapies
- Industry
- Eligibility
- 6 Months to 60 Months
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Stanford, California • Orlando, Florida + 8 more
- Conditions
- Spinal Muscular Atrophy
- Interventions
- 4-aminopyridine, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Spinal Muscular Atrophy Type 3, Ambulatory Spinal Muscular Atrophy
- Interventions
- Not listed
- Lead sponsor
- Jacqueline Montes
- Other
- Eligibility
- 8 Years to 50 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
- Interventions
- taldefgrobep alfa, Placebo
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 27 more
- Conditions
- Osteopenia, Spinal Muscular Atrophy, Cerebral Palsy, Muscular Dystrophy, Spina Bifida, Rett Syndrome
- Interventions
- Assisted Standing Treatment Program
- Other
- Lead sponsor
- Gillette Children's Specialty Healthcare
- Other
- Eligibility
- 3 Years to 14 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota